The company's technology helps scientists discover small molecules for the treatment and investigation of human diseases. Atomwise is focused on its own internal pipeline and has a Scientific Advisory Board. They have developed a pipeline of small-molecule drug candidates advancing into preclinical studies and have unlocked more undruggable targets than any other AI drug discovery platform. They are tackling over 600 unique disease targets with more than 250 partners worldwide and have raised over $174 million from leading venture capital firms to advance their mission of making better medicines faster. Atomwise believes that advancing technology and scientific breakthroughs can accelerate discovery and ultimately save one billion lives.